Kirsten Greene, MD

Urologic cancer surgeon

Dr. Kirsten Greene specializes in urologic cancers, particularly prostate and bladder cancer, at the UCSF Helen Diller Family Comprehensive Cancer Center. Her interests include the screening, diagnosis and management of genitourinary malignancy and minimally invasive treatment of urologic disease. She has experience with robotic, laparoscopic and endoscopic surgery and is involved in the development of new technologies and the creation of guidelines of care for urologic malignancies.

Greene earned a medical degree at Johns Hopkins University School of Medicine and completed general surgery and urology training at UCSF. She is combining her interest in urologic oncology, minimally invasive surgery and outcomes research by pursuing a master's degree in clinical research at UCSF while serving as a clinical instructor in the UCSF Department of Urology.

Clinics

Prostate Cancer Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Medical Oncology Phone: (415) 476-4616
Surgical Oncology Phone: (415) 353-7171
Medical Oncology Fax: (415) 353-7107
Surgical Oncology Fax: (415) 514-6195

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgical Oncology Clinic
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
New Patient Fax: (415) 514-6195
General Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Board Certification

Urology, American Board of Urology

Academic Title

Associate Professor

More about Kirsten Greene

Education

Johns Hopkins University School of Medicine 2000

Residencies

UCSF Medical Center, Urology 2006

Selected Research and Publications

  1. Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol. 2018 Apr; 199(4):990-997.
  2. Awad MA, Gaither TW, Osterberg EC, Yang G, Greene KL, Weiss DA, Anger JT, Breyer BN. Gender differences in promotions and scholarly productivity in academic urology. Can J Urol. 2017 Oct; 24(5):9011-9016.
  3. Starobinets O, Simko JP, Kuchinsky K, Kornak J, Carroll PR, Greene KL, Kurhanewicz J, Noworolski SM. Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard. NMR Biomed. 2017 Dec; 30(12).
  4. Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll PR, Hope TA. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res. 2017 Sep 19; 7(1):77.
  5. Chang I, Mitsui Y, Kim SK, Sun JS, Jeon HS, Kang JY, Kang NJ, Fukuhara S, Gill A, Shahryari V, Tabatabai ZL, Greene KL, Dahiya R, Shin DM, Tanaka Y. Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation. Oncotarget. 2017 Jun 13; 8(24):39087-39100.
  6. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 Dec; 58(12):1956-1961.
  7. Bucay N, Bhagirath D, Sekhon K, Yang T, Fukuhara S, Majid S, Shahryari V, Tabatabai Z, Greene KL, Hashimoto Y, Shiina M, Yamamura S, Tanaka Y, Deng G, Dahiya R, Saini S. A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition. Cell Death Differ. 2017 07; 24(7):1263-1274.
  8. Tzou DT, Weinstein S, Usawachintachit M, Mongan J, Greene KL, Chi T. Contrast Enhanced Ultrasound Detects Recurrent Renal Cell Carcinoma in the Setting of Chronic Renal Insufficiency. Clin Genitourin Cancer. 2017 Aug; 15(4):e735-e737.
  9. Bucay N, Sekhon K, Majid S, Yamamura S, Shahryari V, Tabatabai ZL, Greene K, Tanaka Y, Dahiya R, Deng G, Saini S. Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer. Oncotarget. 2016 Oct 25; 7(43):70388-70403.
  10. Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, Yamamura S, Mitsui Y, Tanaka Y, Kato T, Hashimoto Y, Shiina M, Kulkarni P, Dasgupta P, Imai-Sumida M, Tabatabai ZL, Greene K, Deng G, Dahiya R, Majid S. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget. 2016 Oct 18; 7(42):68371-68384.
  11. Nguyen HG, Punnen S, Cowan JE, Leapman M, Cary C, Welty C, Weinberg V, Cooperberg MR, Meng MV, Greene KL, Garcia M, Carroll PR. A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. J Urol. 2017 Feb; 197(2):369-375.
  12. Shahryari V, Nip H, Saini S, Dar AA, Yamamura S, Mitsui Y, Colden M, Bucay N, Tabatabai LZ, Greene K, Deng G, Tanaka Y, Dahiya R, Majid S. Pre-clinical Orthotopic Murine Model of Human Prostate Cancer. J Vis Exp. 2016 Aug 29; (114).
  13. Scherr KA, Fagerlin A, Hofer T, Scherer LD, Holmes-Rovner M, Williamson LD, Kahn VC, Montgomery JS, Greene KL, Zhang B, Ubel PA. Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions. Med Decis Making. 2017 01; 37(1):56-69.
  14. Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene KL. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncol. 2016 Nov; 12(21):2393-2396.
  15. Roberge G, Stortz SK, Frankel WC, Greene KL, Deng DY. Identifying Prevalence and Risk Factors for Mild Cognitive Impairment in Adults Presenting for Urological Evaluation. Urology. 2016 Aug; 94:29-35.
  16. Porten SP, Leapman MS, Greene KL. Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol. 2015 Oct-Dec; 31(4):297-303.
  17. Bucay N, Shahryari V, Majid S, Yamamura S, Mitsui Y, Tabatabai ZL, Greene K, Deng G, Dahiya R, Tanaka Y, Saini S. miRNA Expression Analyses in Prostate Cancer Clinical Tissues. J Vis Exp. 2015 Sep 08; (103).
  18. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M, Chang AJ, Chan JM, Simko JP, Carroll PR. Patterns of Local Failure following Radiation Therapy for Prostate Cancer. J Urol. 2015 Oct; 194(4):977-82.
  19. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11.
  20. Chang I, Fukuhara S, Wong DK, Gill A, Mitsui Y, Majid S, Saini S, Yamamura S, Chiyomaru T, Hirata H, Ueno K, Arora S, Shahryari V, Deng G, Tabatabai ZL, Greene KL, Shin DM, Enokida H, Shiina H, Nonomura N, Dahiya R, Tanaka Y. Cytochrome P450 1B1 polymorphisms and risk of renal cell carcinoma in men. Tumour Biol. 2014 Oct; 35(10):10223-30.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.